Merck KGaA’s life science unit is still feeling the Covid demand declinenews2024-11-14T14:29:08+00:00November 14th, 2024|Endpoints News|
Merck buys into PD-1/VEGF space as Summit comes for Keytrudanews2024-11-14T12:29:52+00:00November 14th, 2024|Endpoints News|
FDA approves PTC’s ultra-rare disease gene therapynews2024-11-14T05:11:24+00:00November 14th, 2024|Endpoints News|
J&J takes 340B fight with federal government to courtnews2024-11-13T16:34:31+00:00November 13th, 2024|Endpoints News|
After stock slides, Amgen addresses bone density talk on obesity drugnews2024-11-13T12:20:55+00:00November 13th, 2024|Endpoints News|
BioNTech buys out partner Biotheus for PD-L1/VEGF cancer drugnews2024-11-13T11:45:55+00:00November 13th, 2024|Endpoints News|
Pfizer looking to sell hospital drugs unit — reportsnews2024-11-12T21:05:47+00:00November 12th, 2024|Endpoints News|
AstraZeneca CEO reaffirms commitment to China following executive’s detentionnews2024-11-12T20:43:03+00:00November 12th, 2024|Endpoints News|
Syndax’s menin inhibitor succeeds in pivotal trial, but investors aren’t impressednews2024-11-12T20:29:16+00:00November 12th, 2024|Endpoints News|
Merck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosisnews2024-11-12T19:48:28+00:00November 12th, 2024|Endpoints News|
